LABORATORIO FARMACEUTICO ERFO S.P.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.14 EUR | +2.24% |
|
+3.64% | -12.98% |
| 03-29 | Laboratorio Farmaceutico Erfo, revenues grow and profit remains stable | AN |
| 02-19 | Mib in the red at 31,600; TIM still on top | AN |
| Sales 2023 * | 6.3M 6.74M 539M | Sales 2024 * | 6.5M 6.95M 557M | Capitalization | 10.26M 10.97M 878M |
|---|---|---|---|---|---|
| Net income 2023 * | - 0 0 | Net income 2024 * | - 0 0 | EV / Sales 2023 * | 1.37 x |
| Net cash position 2023 * | 1.6M 1.71M 137M | Net cash position 2024 * | 2M 2.14M 171M | EV / Sales 2024 * | 1.27 x |
| P/E ratio 2023 * |
12.7
x | P/E ratio 2024 * |
19
x | Employees | 29 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 22.6% |
More Fundamentals
* Assessed data
More news
More news
| 1 day | +2.24% | ||
| 1 week | +3.64% | ||
| Current month | +5.07% | ||
| 1 month | +4.59% | ||
| 3 months | -2.15% | ||
| 6 months | +26.11% | ||
| Current year | -12.98% |
1 week
1.10
1.15
1 month
1.101.24
Current year
0.971.33
1 year
0.881.34
3 years
0.883.30
5 years
0.883.30
10 years
0.883.30
| Managers | Title | Age | Since |
|---|---|---|---|
Flavio Corpina
CEO | Chief Executive Officer | 45 | 31/12/16 |
Alessandro Cutè
CEO | Chief Executive Officer | 53 | 31/12/12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alessandro Cutè
CEO | Chief Executive Officer | 53 | 31/12/12 |
Flavio Corpina
CEO | Chief Executive Officer | 45 | 31/12/16 |
Fabio Giuffre
BRD | Director/Board Member | 43 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 1.14 | +2.24% | 1,000 |
| 25/04/24 | 1.115 | -1.33% | 4,000 |
| 24/04/24 | 1.13 | 0.00% | 0 |
| 23/04/24 | 1.13 | +2.73% | 9,000 |
| 22/04/24 | 1.1 | 0.00% | 0 |
Real-time Borsa Italiana, April 26, 2024 at 04:44 pm
More quotes
Laboratorio Farmaceutico Erfo SpA is an Italy-based pharmaceutical company primarily engaged in the nutraceutical sector. The Company specializes in the production of nutritional supplements, that thanks to research and development carried out internally and in collaboration with the University Campus Bio-Medico of Rome and the University of Messina provides products with a scientific value in different therapeutic areas. The Company operates globally.
Sector
Pharmaceuticals
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.14
EUR
Average target price
1.47
EUR
Spread / Average Target
+28.95%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -12.98% | 10.95M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- ERFO Stock
